Oncotarget

Research Papers:

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447

Tara L. Peters, Lingxiao Li, Ana A. Tula-Sanchez, Praechompoo Pongtornpipat and Jonathan H. Schatz _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:63362-63373. https://doi.org/10.18632/oncotarget.11457

Metrics: PDF 1774 views  |   HTML 3006 views  |   ?  


Abstract

Tara L. Peters1, Lingxiao Li2, Ana A. Tula-Sanchez3, Praechompoo Pongtornpipat4, Jonathan H. Schatz2

1Sheila and David Fuente Graduate Program in Cancer Biology, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

2Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

3Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ, USA

4Bio5 Institute, University of Arizona, Tucson, AZ, USA

Correspondence to:

Jonathan H. Schatz, email: [email protected]

Keywords: ABC-DLBCL, PIM kinase, cap-dependent translation, B-cell receptor signaling, lymphomagenesis

Received: October 05, 2015     Accepted: August 05, 2016     Published: August 20, 2016

ABSTRACT

The PIM family kinases promote growth and survival of tumor cells and are expressed in a wide variety of human cancers. Their potential as therapeutic targets, however, is complicated by overlapping activities with multiple other pathways and remains poorly defined in most clinical scenarios. Here we explore activity of the new pan-PIM inhibitor PIM447 in a variety of lymphoid-derived tumors. We find strong activity in cell lines derived from the activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL). Sensitive lines show lost activation of the mTORC1 signaling complex and subsequent lost activation of cap-dependent protein translation. In addition, we characterize recurrent PIM1 protein-coding mutations found in DLBCL clinical samples and find most preserve the wild-type protein’s ability to protect cells from apoptosis but do not bypass activity of PIM447. Pan-PIM inhibition therefore may have an important role to play in the therapy of selected ABC-DLBCL cases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11457